Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explantsTala Tayoun(Centre National de la Recherche Scientifique), Françoise Farace(Institut Gustave Roussy)JCI InsightMay 5, 202210.1172/jci.insight.155804Cited by 43SaveCiteExport RISWatch citationsRelated PapersEfficacy, Safety, and Biomarkers of Single-Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma|The Oncologist|2012|132Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model|Nature Communications|2020|80Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study|Oncotarget|2016|36Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors|Cancer Research|2008|8